<DOC>
	<DOCNO>NCT01348256</DOCNO>
	<brief_summary>In randomize multicentric phase II study , patient colorectal carcinoma resectable hepatic metastasis randomize treatment dendritic cell observation , follow conventional treatment surgery chemotherapy .</brief_summary>
	<brief_title>Study With Dendritic Cell Immunotherapy Resected Hepatic Metastasis Colorectal Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Neoplasms , Second Primary</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1 . Age 18 year . 2 . Confirmed diagnosis colorectal cancer hepatic metastasis , amenable surgical treatment . 3 . Capacity understand signing informed consent undergo study procedures 4 . Availability tumor tissue , mature dendritic cell 5 . Adequate renal , hepatic bone marrow function 1 . Clinically relevant disease infection . 2 . Concurrent participation clinical trial administration antitumoral treatment 3 . Concurrent cancer , exception allow principal investigator ( PI ) . 4 . Pregnant breast feed woman 5 . Immunosuppressant treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>colorectal carcinoma</keyword>
	<keyword>resectable hepatic metastasis</keyword>
	<keyword>adjuvant treatment</keyword>
	<keyword>dendritic cell</keyword>
</DOC>